The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 1107-1114

  Stiekema, Jurriën ^a   Trip, Anouk K ^a   Jansen, Edwin P M ^a   Boot, Henk ^a   Cats, Annemieke ^a   Ponz, Olga Balague ^a   Verheij, Marcel ^a   Van Sandick, Johanna W ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURGERY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL GASTRECTOMY; PERITONEUM METASTASIS; RADIATION DOSE; RECURRENCE FREE SURVIVAL; STOMACH CANCER; TOTAL STOMACH RESECTION; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84896079273     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3397-4     Document Type: Article

References (31)

1. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4: survival of cancer patients diagnosed in 1995-1999-results and commentary. Eur J Cancer. 2009;45:931-91.
2. Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113-9. (Pubitemid 37152170)
3. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808-16. (Pubitemid 39425773)
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
5. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327-33.
6. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268-73.
7. ZhuWG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104:361-6.
8. Raziee HR, Cardoso R, Seevaratnam R, et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer. 2011;15:116-24.
9. Morgagni P, Garcea D, Marrelli D, et al. Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. World J Surg. 2008;32:2661-7.
10. Papachristou DN, Agnanti N, D'Agostino H, Fortner JG. Histologically positive esophageal margin in the surgical treatment of gastric cancer. Am J Surg. 1980;139:711-3. (Pubitemid 10102052)
11. Sun Z, Li DM, Wang ZN, et al. Prognostic significance of microscopic positive margins for gastric cancer patients with potentially curative resection. Ann Surg Oncol. 2009;16:3028-37.
12. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
13. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma-an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
14. Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M. Postoperative chemoradiotherapy in gastric cancer: a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer. 2007;97:712-6. (Pubitemid 47396299)
15. Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 2007;69:1424-8. (Pubitemid 350116396)
16. Jansen EP, Boot H, Dubbelman R, Verheij M, Cats A. Postoperative chemoradiotherapy in gastric cancer: a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Ann Oncol. 2010;21:530-4.
17. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
18. Wang SY, Yeh CN, Lee HL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738-43.
19. Kim SH, Karpeh MS, Klimstra DS, Leung D, Brennan MF. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg. 1999;3:24-33.
20. Songun I, Bonenkamp JJ, Hermans J, van Krieken JH, van de Velde CJ. Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer. 1996;32A:433-7.
21. Hofheinz RD, Wenz F, Lukan N, et al. Oxaliplatin and capecit-abine-based chemoradiotherapy for gastric cancer : an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys. 2009;73:142-7.
22. Kassam Z, Lockwood G, O'Brien C, et al. Conformal radiotherapy in the adjuvant treatment of gastric cancer: review of 82 cases. Int J Radiat Oncol Biol Phys. 2006;65:713-9. (Pubitemid 43795861)
23. Hughes BG, Yip D, Chao M, et al. Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. Aust N Z J Surg. 2004;74:951-6.
24. Tsang WK, Leung SF, Chiu SK, et al. Adjuvant chemoradiation for gastric cancer: experience in the Chinese population. Clin Oncol (R Coll Radiol). 2007;19:333-40. (Pubitemid 46760602)
25. Chang AT, Ng WT, Law AL, Ku KM, Lee MC, Lee AW. Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer. 2011;14:63-71.
26. Kundel Y, Purim O, Idelevich E, et al. Postoperative chemoradiation for resected gastric cancer: is the Macdonald regimen tolerable? A retrospective multi-institutional study. Radiat Oncol. 2011;6:127.
27. Lee JH, Ahn SH, Park do J, Kim HH, Lee HJ, Yang HK. Clinical impact of tumor infiltration at the transected surgical margin during gastric cancer surgery. J Surg Oncol. 2012;106:772-6.
28. Cheng CT, Tsai CY, Hsu JT, et al. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol. 2011;18:1606-14.
29. Chen JD, Yang XP, Shen JG, Hu WX, Yuan XM, Wang LB. Prognostic improvement of reexcision for positive resection margins in patients with advanced gastric cancer. Eur J Surg Oncol. 2013;39:229-34.
30. Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28:2430-6.
31. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.